About Suven Life Sciences Limited
Data last updated: 06 January 2026
Suven Life Sciences Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Jasti Property And Equity Holdings Private Limited. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 09 March 1989, the company has been in operation for over 37 years.
Registered with ROC Hyderabad under CIN L24110AP1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN.
Capital: an authorised share capital of ₹50 Cr and a paid-up capital of ₹22.75 Cr. Formerly known as Suven Synthesis Ltd and Suven Pharmaceuticals Pvt Ltd. It is led by directors including Santanu Mukherjee and Sudharani Jasti.
Last AGM: 22 August 2025. Financial statements filed for year ended 31 March 2025. Office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034.
As per the financials filed for FY 2025, the company reported a revenue of ₹17.55 Cr, a decline of 47% compared to the previous year.
The company has a workforce of approximately 137 employees as per the latest available data. It operates as a subsidiary of Jasti Property And Equity Holdings Private Limited.
The company is associated with 3 brands - Suven Nishtaa, Suven Life Sciences, Suven Pharma. As per MCA filings, the company has satisfied charges of ₹239.04 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website suven.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressDoor No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Suven Life Sciences Limited
Suven Life Sciences Limited has undergone 2 name changes throughout its history. The company was previously known as Suven Synthesis Ltd, and Suven Pharmaceuticals Pvt Ltd. The current legal name is Suven Life Sciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Suven Life Sciences Limited | Current |
| Suven Synthesis Ltd | Previous |
| Suven Pharmaceuticals Pvt Ltd | Previous |
CIN History of Suven Life Sciences Limited
Suven Life Sciences Limited has one previous CIN (Corporate Identification Number): L24110AP1989PLC009713. The current CIN is L24110TG1989PLC009713, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24110TG1989PLC009713 | Current |
| L24110AP1989PLC009713 | Previous |
Associated Brands with Suven Life Sciences Limited
Suven Life Sciences Limited operates multiple associated brands including Suven Nishtaa, Suven Life Sciences, and Suven Pharma. These brands represent Suven Life Sciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Online drug store | suvennishtaa.com | |
| CDMO services and CNS drug discovery pipeline are offered. | suven.com | |
| Contract manufacturing and development of APIs and formulations are provided. | suvenpharm.com |
Competitors & Alternatives of Suven Life Sciences Limited
Brands and companies operating in the same space as Suven Life Sciences Limited include Concord Biotech, BDR Pharmaceuticals Internationals, Almac Group and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Pharmaceutics International
|
Pharmaceutical dosage forms are manufactured by this CDMO. | Hunt Valley, United States, United States | 1994 |
Aurobindo Pharma
|
Generic biocatalytic solutions are provided for pharmaceutical applications. | Hyderabad, India, India | 1986 |
Seqens
|
Contract manufacturing services for small molecules and peptides are provided. | Ecully, France, France | 2003 |
Asymchem
|
APIs and peptides are developed and manufactured by Asymchem. | Morrisville, United States, United States | 1995 |
Aptuit
|
Contract research and development services for small molecules are offered. | Greenwich, United States, United States | 2004 |
Continuus Pharma
|
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development | Woburn, United States, United States | 2012 |
Business Activity of Suven Life Sciences Limited
Suven Life Sciences Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Suven Life Sciences Limited
Suven Life Sciences Limited is audited by KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) for the financial year 2025, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| KARVY & Co. (ICAI peer reviewed, certificate valid till 2024-10-31) | FY 2025 | Declaration of unmodified opinion |
Board of Directors of Suven Life Sciences Limited
Suven Life Sciences Limited is currently managed by 8 directors, with 17 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Santanu Mukherjee
Also directs:
Aurobindo Pharma Ltd, Sumedha Fiscal Services Ltd, Rainbow Children's Medicare Limited and 4 more
|
Director | 15 May 2018 | 8 Years 1 Months | Current |
| Sudharani Jasti | Whole-Time Director | 04 Jan 2013 | 13 Years 6 Months | Current |
|
Venkateswarlu Jasti
Also directs:
Svsmk Property Llp, Jasti Property And Equity Holdings Private Limited, Svj Property Holdings Llp and 5 more
|
Managing Director | 04 Jan 2010 | 16 Years 6 Months | Current |
| Vajja Sambasiva Rao | Director | 30 Jan 2024 | 2 Years 5 Months | Current |
| Seyed Ehtesham Hasnain | Director | 30 Apr 2010 | 16 Years 2 Months | Current |
| Ananthasai Padmaja Jasthi | Director | 14 Nov 2018 | 7 Years 7 Months | Current |
Financials of Suven Life Sciences Limited FY 2026 filings available
Suven Life Sciences Limited reported revenue of ₹7.11 Cr (up 6.89% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.11 Cr | ₹6.66 Cr | ₹11.69 Cr | ₹13.54 Cr | ₹11.84 Cr | ₹13.48 Cr | ₹14.41 Cr |
| Other Income | ₹13.93 Cr | ₹10.9 Cr | ₹21.13 Cr | ₹8.45 Cr | ₹5.32 Cr | ₹7.75 Cr | ₹14.04 Cr |
| Total Income | ₹21.04 Cr | ₹17.55 Cr | ₹32.82 Cr | ₹21.99 Cr | ₹17.16 Cr | ₹21.23 Cr | ₹28.45 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹24.15 Cr | ₹20.82 Cr | ₹18.99 Cr | ₹18.62 Cr | ₹21.02 Cr | ₹18.53 Cr | ₹17.41 Cr |
| Finance Costs | ₹15.78 Lakh | ₹4.66 Lakh | ₹15.84 Lakh | ₹28.91 Lakh | ₹53.01 Lakh | ₹81.54 Lakh | ₹55.14 Lakh |
| Depreciation & Amortisation | ₹5.61 Cr | ₹5.82 Cr | ₹6.5 Cr | ₹6.54 Cr | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr |
| Other Expenses | ₹267.47 Cr | ₹151.6 Cr | ₹120.71 Cr | ₹120.8 Cr | ₹113.21 Cr | ₹75.02 Cr | ₹112.72 Cr |
| Total Expenses | ₹297.39 Cr | ₹178.3 Cr | ₹146.36 Cr | ₹146.26 Cr | ₹139.16 Cr | ₹98.71 Cr | ₹134.85 Cr |
| Profit Before Exceptional Items & Tax | -₹276.34 Cr | -₹160.75 Cr | -₹113.54 Cr | -₹124.27 Cr | -₹122 Cr | -₹77.47 Cr | -₹106.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹7.46 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹276.34 Cr | -₹160.75 Cr | -₹106.08 Cr | -₹118.27 Cr | -₹122 Cr | -₹77.47 Cr | -₹106.4 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | -₹5.32 Cr | -₹12.18 Cr |
| Net Profit | -₹276.34 Cr | -₹160.75 Cr | -₹105.08 Cr | -₹118.27 Cr | -₹122 Cr | -₹72.15 Cr | -₹94.22 Cr |
| attributable to Owners | - | - | - | ₹0 | ₹0 | ₹0 | - |
| attributable to NCI | - | - | - | ₹0 | ₹0 | ₹0 | - |
| Other Comprehensive Income | -₹1.18 Cr | -₹58.33 Lakh | -₹6 Lakh | ₹18.99 Lakh | -₹15.05 Lakh | -₹30.67 Lakh | -₹29.54 Lakh |
| Total Comprehensive Income | -₹277.53 Cr | -₹161.33 Cr | -₹105.14 Cr | -₹118.08 Cr | -₹122.15 Cr | -₹72.46 Cr | -₹94.51 Cr |
| EBITDA (computed) | -₹270.57 Cr | -₹154.88 Cr | -₹106.87 Cr | -₹117.44 Cr | -₹117.07 Cr | -₹72.31 Cr | -₹101.68 Cr |
| Basic EPS | ₹-12.13 | ₹-7.37 | ₹-4.82 | ₹-6.63 | ₹-9.57 | ₹-5.67 | ₹-2.01 |
| Diluted EPS | ₹-12.13 | ₹-7.37 | ₹-4.82 | ₹-6.63 | ₹-9.57 | ₹-5.67 | ₹-7.40 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹624.21 Cr | ₹135.18 Cr | ₹284.9 Cr | ₹388.91 Cr |
| Non-current Assets | ₹77.51 Cr | ₹59.71 Cr | ₹28.23 Cr | ₹137.32 Cr |
| Current Assets | ₹546.71 Cr | ₹75.47 Cr | ₹256.67 Cr | ₹251.59 Cr |
| Property, Plant & Equipment | ₹55.7 Cr | ₹59.47 Cr | ₹27.5 Cr | ₹35.73 Cr |
| Inventories | ₹10.2 Lakh | ₹23.75 Lakh | ₹70.85 Lakh | ₹0 |
| Trade Receivables | ₹1.51 Cr | ₹1.34 Cr | ₹1.29 Cr | ₹80.74 Lakh |
| Cash & Equivalents | ₹8.28 Cr | ₹15.03 Cr | ₹14.93 Cr | ₹37.02 Cr |
| Equity (Net Worth) | ₹591.4 Cr | ₹109.99 Cr | ₹270.04 Cr | ₹375.32 Cr |
| Equity Share Capital | ₹26.37 Cr | ₹21.81 Cr | ₹21.81 Cr | ₹21.81 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹30.9 Cr | ₹23.49 Cr | ₹13.52 Cr | ₹11.13 Cr |
| Total Liabilities | ₹32.81 Cr | ₹25.2 Cr | ₹14.86 Cr | ₹13.59 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹301.79 Cr | -₹154.1 Cr | -₹82.62 Cr | -₹207.93 Cr | -₹127.54 Cr |
| Investing Cash Flow | -₹462.11 Cr | ₹154.95 Cr | ₹61.59 Cr | -₹155.71 Cr | -₹22.23 Cr |
| Financing Cash Flow | ₹757.15 Cr | -₹75.63 Lakh | -₹1.05 Cr | ₹395.54 Cr | ₹145.69 Cr |
| Capital Expenditure | ₹5.08 Cr | ₹37.28 Cr | -₹2.42 Cr | ₹2.89 Cr | ₹19.77 Cr |
| Free Cash Flow (computed) | -₹306.87 Cr | -₹191.38 Cr | -₹85.04 Cr | -₹210.82 Cr | -₹147.31 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹6.75 Cr | ₹9.31 Lakh | -₹22.09 Cr | ₹31.75 Cr | -₹4.07 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.52 Cr | ₹2.81 Cr | ₹91.92 Lakh | ₹1.87 Cr | ₹1.47 Cr | ₹1.61 Cr | ₹2.57 Cr | ₹1.01 Cr | ₹2.39 Cr | ₹2.45 Cr | ₹3.06 Cr | ₹3.8 Cr |
| Other Income | ₹6.78 Cr | ₹2.77 Cr | ₹3.78 Cr | ₹59.98 Lakh | ₹1.22 Cr | ₹1.63 Cr | ₹4.04 Cr | ₹4.01 Cr | ₹4.28 Cr | ₹6.07 Cr | ₹5.14 Cr | ₹5.64 Cr |
| Total Income | ₹8.3 Cr | ₹5.58 Cr | ₹4.7 Cr | ₹2.47 Cr | ₹2.69 Cr | ₹3.24 Cr | ₹6.61 Cr | ₹5.01 Cr | ₹6.67 Cr | ₹8.52 Cr | ₹8.2 Cr | ₹9.44 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹5.83 Cr | ₹6.27 Cr | ₹6.08 Cr | ₹5.98 Cr | ₹6.07 Cr | ₹4.87 Cr | ₹5.2 Cr | ₹4.69 Cr | ₹3.46 Cr | ₹5.79 Cr | ₹4.45 Cr | ₹5.28 Cr |
| Finance Costs | ₹15.78 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹79,000 | ₹1.56 Lakh | ₹2.31 Lakh | ₹2.99 Lakh | ₹3.54 Lakh | ₹4.19 Lakh | ₹5.12 Lakh |
| Depreciation & Amortisation | ₹1.58 Cr | ₹1.35 Cr | ₹1.32 Cr | ₹1.37 Cr | ₹1.35 Cr | ₹1.53 Cr | ₹1.46 Cr | ₹1.49 Cr | ₹1.51 Cr | ₹1.6 Cr | ₹1.73 Cr | ₹1.66 Cr |
| Other Expenses | ₹46.32 Cr | ₹99.89 Cr | ₹74.61 Cr | ₹46.64 Cr | ₹39.22 Cr | ₹35.95 Cr | ₹49.58 Cr | ₹26.85 Cr | ₹29.21 Cr | ₹42.85 Cr | ₹22.12 Cr | ₹26.53 Cr |
| Total Expenses | ₹53.89 Cr | ₹107.51 Cr | ₹82.01 Cr | ₹53.98 Cr | ₹46.63 Cr | ₹42.36 Cr | ₹56.25 Cr | ₹33.05 Cr | ₹34.21 Cr | ₹50.28 Cr | ₹28.34 Cr | ₹33.53 Cr |
| Profit Before Exceptional Items & Tax | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹27.54 Cr | -₹41.76 Cr | -₹20.14 Cr | -₹24.09 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.46 Cr | ₹0 |
| Profit Before Tax | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹27.54 Cr | -₹41.76 Cr | -₹12.68 Cr | -₹24.09 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹45.6 Cr | -₹101.92 Cr | -₹77.31 Cr | -₹51.52 Cr | -₹43.94 Cr | -₹39.12 Cr | -₹49.64 Cr | -₹28.04 Cr | -₹26.54 Cr | -₹41.76 Cr | -₹12.68 Cr | -₹24.09 Cr |
| attributable to Owners | - | - | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | - | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹46.66 Lakh | -₹75.13 Lakh | ₹8.52 Lakh | -₹5.12 Lakh | -₹56.98 Lakh | -₹45,000 | -₹45,000 | -₹45,000 | -₹20.24 Lakh | ₹4.75 Lakh | ₹4.75 Lakh | ₹4.75 Lakh |
| Total Comprehensive Income | -₹46.06 Cr | -₹102.67 Cr | -₹77.22 Cr | -₹51.57 Cr | -₹44.51 Cr | -₹39.12 Cr | -₹49.65 Cr | -₹28.04 Cr | -₹26.74 Cr | -₹41.72 Cr | -₹12.63 Cr | -₹24.04 Cr |
| EBITDA (computed) | -₹43.86 Cr | -₹100.58 Cr | -₹75.99 Cr | -₹50.15 Cr | -₹42.6 Cr | -₹37.58 Cr | -₹48.17 Cr | -₹26.53 Cr | -₹26 Cr | -₹40.13 Cr | -₹18.37 Cr | -₹22.37 Cr |
| Basic EPS | ₹-2.02 | ₹-4.55 | ₹-3.48 | ₹-2.36 | ₹-2.02 | ₹-1.79 | ₹-2.27 | ₹-1.29 | ₹-1.22 | ₹-1.92 | ₹-0.58 | ₹-1.10 |
| Diluted EPS | ₹-2.02 | ₹-4.55 | ₹-3.48 | ₹-2.36 | ₹-2.02 | ₹-1.79 | ₹-2.27 | ₹-1.29 | ₹-1.22 | ₹-1.92 | ₹-0.58 | ₹-1.10 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹7.11 Cr | ₹6.66 Cr | ₹11.69 Cr | ₹13.54 Cr | ₹11.84 Cr | ₹13.48 Cr | ₹14.41 Cr |
| Other Income | ₹13.91 Cr | ₹10.73 Cr | ₹21.13 Cr | ₹8.45 Cr | ₹5.32 Cr | ₹7.75 Cr | ₹14.04 Cr |
| Total Income | ₹21.03 Cr | ₹17.38 Cr | ₹32.82 Cr | ₹21.99 Cr | ₹17.16 Cr | ₹21.23 Cr | ₹28.45 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹24.15 Cr | ₹20.82 Cr | ₹16.53 Cr | ₹15.77 Cr | ₹17.46 Cr | ₹15.29 Cr | ₹14.6 Cr |
| Finance Costs | ₹15.78 Lakh | ₹4.66 Lakh | ₹15.84 Lakh | ₹28.91 Lakh | ₹53.01 Lakh | ₹81.54 Lakh | ₹54.03 Lakh |
| Depreciation & Amortisation | ₹5.61 Cr | ₹5.82 Cr | ₹6.5 Cr | ₹6.54 Cr | ₹4.39 Cr | ₹4.35 Cr | ₹4.17 Cr |
| Other Expenses | ₹45.97 Cr | ₹37.77 Cr | ₹26.1 Cr | ₹25.51 Cr | ₹31.02 Cr | ₹28.74 Cr | ₹35.08 Cr |
| Total Expenses | ₹75.89 Cr | ₹64.46 Cr | ₹49.29 Cr | ₹48.12 Cr | ₹53.41 Cr | ₹49.19 Cr | ₹54.39 Cr |
| Profit Before Exceptional Items & Tax | -₹54.86 Cr | -₹47.08 Cr | -₹16.47 Cr | -₹26.13 Cr | -₹36.25 Cr | -₹27.95 Cr | -₹25.94 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹7.46 Cr | ₹6 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹54.86 Cr | -₹47.08 Cr | -₹9.01 Cr | -₹20.13 Cr | -₹36.25 Cr | -₹27.95 Cr | -₹25.94 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | -₹5.32 Cr | -₹12.18 Cr |
| Net Profit | -₹54.86 Cr | -₹47.08 Cr | -₹8.01 Cr | -₹20.13 Cr | -₹36.25 Cr | -₹22.63 Cr | -₹13.75 Cr |
| Other Comprehensive Income | -₹22.19 Lakh | -₹5.69 Lakh | -₹6 Lakh | ₹18.99 Lakh | -₹15.05 Lakh | -₹30.67 Lakh | -₹29.54 Lakh |
| Total Comprehensive Income | -₹55.08 Cr | -₹47.14 Cr | -₹8.07 Cr | -₹19.94 Cr | -₹36.4 Cr | -₹22.94 Cr | -₹14.05 Cr |
| EBITDA (computed) | -₹49.09 Cr | -₹41.21 Cr | -₹9.81 Cr | -₹19.29 Cr | -₹31.33 Cr | -₹22.79 Cr | -₹21.23 Cr |
| Basic EPS | ₹-2.41 | ₹-2.16 | ₹-0.37 | ₹-1.13 | ₹-2.84 | ₹-1.78 | ₹-1.08 |
| Diluted EPS | ₹-2.41 | ₹-2.16 | ₹-0.37 | ₹-1.13 | ₹-2.84 | ₹-1.78 | ₹-1.08 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,531.06 Cr | ₹808.89 Cr | ₹851.48 Cr | ₹860.44 Cr |
| Non-current Assets | ₹990.35 Cr | ₹751.18 Cr | ₹605.34 Cr | ₹619.18 Cr |
| Current Assets | ₹540.71 Cr | ₹57.71 Cr | ₹246.14 Cr | ₹241.26 Cr |
| Property, Plant & Equipment | ₹55.7 Cr | ₹59.47 Cr | ₹27.5 Cr | ₹35.73 Cr |
| Inventories | ₹10.2 Lakh | ₹23.75 Lakh | ₹70.85 Lakh | ₹0 |
| Trade Receivables | ₹1.51 Cr | ₹1.34 Cr | ₹1.29 Cr | ₹80.74 Lakh |
| Cash & Equivalents | ₹2.28 Cr | ₹46.35 Lakh | ₹4.4 Cr | ₹26.7 Cr |
| Equity (Net Worth) | ₹1,503.37 Cr | ₹799.51 Cr | ₹845.38 Cr | ₹853.44 Cr |
| Equity Share Capital | ₹26.37 Cr | ₹21.81 Cr | ₹21.81 Cr | ₹21.81 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹3.75 Cr | ₹7.67 Cr | ₹4.76 Cr | ₹4.54 Cr |
| Total Liabilities | ₹27.7 Cr | ₹9.38 Cr | ₹6.11 Cr | ₹7 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹69.6 Cr | -₹47.39 Cr | ₹12.29 Cr | -₹114.87 Cr | -₹36.62 Cr |
| Investing Cash Flow | -₹685.74 Cr | ₹44.21 Cr | -₹33.53 Cr | -₹256.88 Cr | -₹107.46 Cr |
| Financing Cash Flow | ₹757.15 Cr | -₹75.63 Lakh | -₹1.05 Cr | ₹395.54 Cr | ₹145.69 Cr |
| Capital Expenditure | ₹5.08 Cr | ₹37.28 Cr | -₹2.42 Cr | ₹2.89 Cr | ₹19.77 Cr |
| Free Cash Flow (computed) | -₹74.68 Cr | -₹84.67 Cr | ₹9.87 Cr | -₹117.76 Cr | -₹56.39 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹1.82 Cr | -₹3.94 Cr | -₹22.3 Cr | ₹23.79 Cr | ₹1.61 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.52 Cr | ₹2.81 Cr | ₹91.92 Lakh | ₹1.87 Cr | ₹1.47 Cr | ₹1.61 Cr | ₹2.57 Cr | ₹1.01 Cr | ₹2.39 Cr | ₹2.45 Cr | ₹3.06 Cr | ₹3.8 Cr |
| Other Income | ₹6.78 Cr | ₹2.77 Cr | ₹3.78 Cr | ₹58.9 Lakh | ₹1.19 Cr | ₹1.57 Cr | ₹4.03 Cr | ₹3.93 Cr | ₹4.28 Cr | ₹6.07 Cr | ₹5.14 Cr | ₹5.64 Cr |
| Total Income | ₹8.3 Cr | ₹5.57 Cr | ₹4.7 Cr | ₹2.46 Cr | ₹2.66 Cr | ₹3.18 Cr | ₹6.61 Cr | ₹4.94 Cr | ₹6.67 Cr | ₹8.52 Cr | ₹8.2 Cr | ₹9.44 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹5.83 Cr | ₹6.27 Cr | ₹6.08 Cr | ₹5.98 Cr | ₹6.07 Cr | ₹4.87 Cr | ₹5.2 Cr | ₹4.69 Cr | ₹3.46 Cr | ₹4.32 Cr | ₹4.21 Cr | ₹4.54 Cr |
| Finance Costs | ₹15.78 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹79,000 | ₹1.56 Lakh | ₹2.31 Lakh | ₹2.99 Lakh | ₹3.54 Lakh | ₹4.19 Lakh | ₹5.12 Lakh |
| Depreciation & Amortisation | ₹1.58 Cr | ₹1.35 Cr | ₹1.32 Cr | ₹1.37 Cr | ₹1.35 Cr | ₹1.53 Cr | ₹1.46 Cr | ₹1.49 Cr | ₹1.51 Cr | ₹1.6 Cr | ₹1.73 Cr | ₹1.66 Cr |
| Other Expenses | ₹11.9 Cr | ₹11.43 Cr | ₹12.75 Cr | ₹9.89 Cr | ₹10.32 Cr | ₹10.04 Cr | ₹11.01 Cr | ₹6.4 Cr | ₹5.79 Cr | ₹7.33 Cr | ₹6.92 Cr | ₹6.05 Cr |
| Total Expenses | ₹19.47 Cr | ₹19.05 Cr | ₹20.14 Cr | ₹17.23 Cr | ₹17.73 Cr | ₹16.45 Cr | ₹17.68 Cr | ₹12.6 Cr | ₹10.79 Cr | ₹13.29 Cr | ₹12.9 Cr | ₹12.31 Cr |
| Profit Before Exceptional Items & Tax | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹4.13 Cr | -₹4.77 Cr | -₹4.7 Cr | -₹2.87 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.46 Cr | ₹0 |
| Profit Before Tax | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹4.13 Cr | -₹4.77 Cr | ₹2.76 Cr | -₹2.87 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹11.17 Cr | -₹13.47 Cr | -₹15.45 Cr | -₹14.78 Cr | -₹15.07 Cr | -₹13.27 Cr | -₹11.07 Cr | -₹7.67 Cr | -₹3.12 Cr | -₹4.77 Cr | ₹2.76 Cr | -₹2.87 Cr |
| Other Comprehensive Income | -₹22.45 Lakh | ₹3.26 Lakh | -₹1.5 Lakh | -₹1.5 Lakh | -₹4.64 Lakh | -₹45,000 | -₹45,000 | -₹45,000 | -₹20.24 Lakh | ₹4.75 Lakh | ₹4.74 Lakh | ₹4.75 Lakh |
| Total Comprehensive Income | -₹11.39 Cr | -₹13.44 Cr | -₹15.46 Cr | -₹14.79 Cr | -₹15.12 Cr | -₹13.28 Cr | -₹11.08 Cr | -₹7.67 Cr | -₹3.33 Cr | -₹4.72 Cr | ₹2.8 Cr | -₹2.82 Cr |
| EBITDA (computed) | -₹9.43 Cr | -₹12.13 Cr | -₹14.13 Cr | -₹13.41 Cr | -₹13.72 Cr | -₹11.73 Cr | -₹9.6 Cr | -₹6.16 Cr | -₹2.59 Cr | -₹3.13 Cr | -₹2.93 Cr | -₹1.15 Cr |
| Basic EPS | ₹-0.50 | ₹-0.60 | ₹-0.70 | ₹-0.68 | ₹-0.69 | ₹-0.61 | ₹-0.51 | ₹-0.35 | ₹-0.14 | ₹-0.22 | ₹0.13 | ₹-0.13 |
| Diluted EPS | ₹-0.50 | ₹-0.60 | ₹-0.70 | ₹-0.68 | ₹-0.69 | ₹-0.61 | ₹-0.51 | ₹-0.35 | ₹-0.14 | ₹-0.22 | ₹0.13 | ₹-0.13 |
Board & Governance of Suven Life Sciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Suven Life Sciences Limited has 6 directors - 3 independent and 2 executive. The board is chaired by VENKATESWARLU JASTI.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| VENKATESWARLU JASTI | Executive Director · MD · Chairperson | 1989-03-09 | 2 |
| SUDHARANI JASTI | Executive Director | 1989-03-09 | 1 |
| SEYED EHTESHAM HASNAIN | Non-Executive - Non Independent Director | 2010-04-30 | 1 |
| SANTANU MUKHERJEE | Non-Executive - Independent Director | 2018-05-15 | 4 |
| ANANTHASAI PADMAJA JASTHI | Non-Executive - Independent Director | 2018-11-14 | 1 |
| VAJJA SAMBASIVA RAO | Non-Executive - Independent Director | 2024-01-30 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | SANTANU MUKHERJEE (Chairperson), ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO |
| Nomination and remuneration committee | SANTANU MUKHERJEE (Chairperson), SEYED EHTESHAM HASNAIN, ANANTHASAI PADMAJA JASTHI, VAJJA SAMBASIVA RAO |
| Stakeholders Relationship Committee | VAJJA SAMBASIVA RAO (Chairperson), ANANTHASAI PADMAJA JASTHI, VENKATESWARLU JASTI |
| Risk Management Committee | VENKATESWARLU JASTI (Chairperson), SANTANU MUKHERJEE, VAJJA SAMBASIVA RAO, MOHANKUMAR MALLARAPU |
| Corporate Social Responsibility Committee | VAJJA SAMBASIVA RAO (Chairperson), SEYED EHTESHAM HASNAIN, VENKATESWARLU JASTI |
Charges & Borrowings of Suven Life Sciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Dec 2012 | Bank of Bahrain and Kuwait Bsc | ₹6 Cr | Satisfied |
| 24 Aug 2012 | Bank of Bahrain and Kuwait Bsc | ₹30 Cr | Satisfied |
| 17 Feb 2011 | Bank of India | ₹22.63 Cr | Satisfied |
| 14 Jul 2010 | State of Bank Patiala | ₹20 Cr | Satisfied |
| 30 Aug 2007 | State Bank of India | ₹25.35 Cr | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Suven Life Sciences Limited
View historical data on people associated with Suven Life Sciences Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Suven Life Sciences Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Suven Life Sciences Limited
GSTIN & GST Filing Data of Suven Life Sciences Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Suven Life Sciences Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Suven Life Sciences Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Suven Life Sciences Limited
MSME Payment Delays by Suven Life Sciences Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Suven Life Sciences Limited
Subsidiaries & Group Companies of Suven Life Sciences Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Suven Life Sciences Limited with ownership details.
MCA Filings & Documents of Suven Life Sciences Limited
MCA Filings & Documents of Suven Life Sciences Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Suven Life Sciences Limited
Recent News on Suven Life Sciences Limited
Frequently Asked Questions about Suven Life Sciences Limited
Suven Life Sciences Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 09 March 1989 (37+ years old) and is registered under CIN L24110TG1989PLC009713. Listed on BSE: 530239 and NSE: SUVEN. The company has 137 employees.
Suven Life Sciences Limited reported revenue of ₹17.55 Cr for FY 2025 (down 47.00% YoY).
The current directors of Suven Life Sciences Limited are:
- Santanu Mukherjee
- Mohan Kumar Mallarapu
- Sudharani Jasti
- Venkateswarlu Jasti
- Vajja Sambasiva Rao
- Seyed Ehtesham Hasnain
- Shrenik Soni
- Ananthasai Padmaja Jasthi
The primary industry of Suven Life Sciences Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes. Suven Life Sciences Limited is listed on both BSE (code: 530239) and NSE (symbol: SUVEN).
Suven Life Sciences Limited can be reached at the registered office: Door No. 8 – 2 – 334 6Th Floor Sde Serene Chambers Road No. 5 Avenue 7 Banjara Hills, Hyderabad, Telangana, India – 500034, or through the website suven.com.